Atara Biotherapeutics (ATRA) Accumulated Expenses (2013 - 2026)

Atara Biotherapeutics' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• Quarterly Accumulated Expenses fell 61.86% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 61.86% YoY) and the FY2025 annual result came in at $1.8 million, down 70.17% from the prior year.
• Accumulated Expenses was $1.8 million for Q1 2026 at Atara Biotherapeutics, down from $1.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $19.0 million in Q4 2023 and bottomed at $349000.0 in Q1 2023.
• A 5-year average of $8.4 million and a median of $7.3 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 97.87% — and 2024, when it surged 5115.76%.
• Atara Biotherapeutics' Accumulated Expenses stood at $7.4 million in 2022, then surged by 155.64% to $19.0 million in 2023, then slumped by 68.29% to $6.0 million in 2024, then plunged by 70.17% to $1.8 million in 2025, then retreated by 2.45% to $1.8 million in 2026.
• Business Quant data shows ATRA's Accumulated Expenses at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $2.6 million in Q3 2025.